Physician profile

Frederick D Harris

Internal Medicine · Cleveland Heights, OH

NPI 1831147859

$10,643.03

in general payments reported to CMS, 2019-2025

45 companies · $604 in 2025

The $604 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,344.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $2,353.26 2019-2023
Amgen INC. $1,188.61 2019-2025 Repatha, Repatha, Otezla
Astrazeneca Pharmaceuticals Lp $1,036.40 2019-2023 Breztri, Farxiga
Novo Nordisk INC $959.77 2019-2025 Ozempic, Rybelsus
Glaxosmithkline, LLC. $854.87 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Mylan Specialty L.P. $560.93 2019-2020
Pfizer INC. $478.83 2019-2023
Abbvie INC. $384.64 2020-2022
Globus Medical, INC. $217.42 2019
Boehringer Ingelheim Pharmaceuticals, INC. $204.18 2020-2023
Teva Pharmaceuticals USA, INC. $198.26 2021-2023 Airduo Digihaler
Abbott Laboratories $182.05 2021-2024 Freestyle Libre 3
Olympus America INC. $158.47 2025 Itind System
Astellas Pharma US INC $157.55 2019-2023 Myrbetriq
Biohaven Pharmaceuticals, INC. $153.70 2020-2021
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $148.59 2022-2023
Dendreon Pharmaceuticals LLC $143.82 2025 Provenge
Takeda Pharmaceuticals U.S.A., INC. $139.98 2019-2021
E.R. Squibb & Sons, L.L.C. $133.63 2019-2023 Eliquis
Allergan, INC. $114.80 2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $85.12 2019-2024 Xifaxan
Bayer Healthcare Pharmaceuticals INC. $62.48 2021-2022
Janssen Biotech, INC. $60.69 2024 Stelara
Merck Sharp & Dohme LLC $52.99 2020-2024 Capvaxive, Gardasil 9, Gardasil
Janssen Pharmaceuticals, INC $47.08 2019
Esperion Therapeutics, INC. $46.80 2021
Dexcom, INC. $46.68 2022
Eisai INC. $45.98 2021
Grt US Holding, INC. $45.05 2021
Biohaven Pharmaceutical Holding Company Ltd. $42.97 2022
Xeris Pharmaceuticals, INC. $40.74 2023 Gvoke Hypopen, Keveyis
Horizon Therapeutics Plc $32.98 2021
Hikma Pharmaceuticals USA $32.33 2021-2023 Kloxxado, Ryaltris, Mitigare
Corcept Therapeutics $27.43 2021
Ferring Pharmaceuticals INC. $26.13 2023 Rebyota
Lilly USA, LLC $24.57 2021
Amarin Pharma, INC. $22.37 2022
Exact Sciences Corporation $21.06 2023 Cologuard Collection Kit
Ultragenyx Pharmaceutical INC. $19.55 2020
Phadia US INC. $17.61 2021
Baxter Healthcare $16.84 2022
Eyevance Pharmaceuticals LLC $15.77 2021
Mannkind Corporation $13.67 2019
Ipsen Biopharmaceuticals, INC $13.31 2021
Phathom Pharmaceuticals, INC. $13.07 2024 Voquezna

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Frederick D Harris

$10,643.03

in general payments reported 2019-2025

Years
2019-2025
Top company
Sanofi-Aventis U.S. LLC
Context
The $604 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/37708/frederick-d-harris

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.